Kaiserslautern, Germany

Käthe Gooβen


Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 11(Granted Patents)


Company Filing History:


Years Active: 2011-2013

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Käthe Gooβen: Innovator in Antiviral Medicament Development

Introduction

Käthe Gooβen is a notable inventor based in Kaiserslautern, Germany. He has made significant contributions to the field of medicinal chemistry, particularly in the development of antiviral agents. With a total of 2 patents, his work has the potential to impact the pharmaceutical industry positively.

Latest Patents

Gooβen's latest patents focus on processes for the preparation of dihydroquinazolines. One of his inventions involves a process for creating methyl (S)-{8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoro-methyl)-phenyl]-3,4-dihydroquinazolin-4-yl}acetate (2S,3S)-2,3-bis[(4-methylbenzoyl)-oxy]succinic acid salt. These compounds are essential for the production of antiviral medicaments. Another patent also relates to a process for the preparation of dihydroquinazolines, specifically {8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydroquinazolin-4-yl}acetic acid, which serves as an antiviral agent in medicament production.

Career Highlights

Käthe Gooβen is currently associated with Aicuris GmbH & Co. KG, where he continues to innovate in the field of antiviral research. His work has garnered attention for its potential applications in treating viral infections.

Collaborations

Gooβen collaborates with talented individuals such as Oliver Kuhn and Mathias Berwe, contributing to a dynamic research environment that fosters innovation.

Conclusion

Käthe Gooβen's contributions to antiviral medicament development through his patents highlight his role as a significant inventor in the pharmaceutical industry. His ongoing work promises to advance the field and improve treatment options for viral infections.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…